SARS-CoV-2感染神经性急性后遗症患者脑白质宏观与微观结构差异
横断面研究纳入31例NeuroPASC患者与41例年龄、性别、教育程度匹配的无COVID对照,发现NeuroPASC组脑白质体积更大(β=0.229,95%CI 0.017-0.441,P=.035),白质平均峰度更高,且头痛、注意力、集中力、言语学习和处理速度表现更差,干扰素-λ1和IFN-λ2/3水平更高。
要点
- NeuroPASC患者脑白质体积较无COVID对照增大,以额前和白质前颞叶白质最明显。
- NeuroPASC患者白质平均峰度升高,提示持续神经炎症可能影响白质属性。
- NeuroPASC患者自报症状更多(包括头痛),注意力、集中力、言语学习和处理速度测试表现更低。
核心结论
- NeuroPASC参与者表现出与白质综合征相符的注意力下降、疲劳加重和认知受损,脑白质体积增大且白质平均峰度升高,提示免疫失调可能影响白质属性并产生相应认知效应和头痛。
研究设计与样本
- 横断面研究,筛查159名潜在参与者后纳入72名(31例NeuroPASC,41例年龄、性别、教育程度匹配的无COVID对照),评估包括临床问卷、心理测量、脑MRI和外周细胞因子水平。
关键影像表现/征象
- NeuroPASC组脑白质体积较无COVID对照组增大(β=0.229;95%CI:0.017-0.441;t=2.16;P=.035),效应最明显位于额前和白质前颞叶白质。
- NeuroPASC组白质平均峰度较无COVID对照组升高,与持续神经炎症相符。
- NeuroPASC组自报症状更多,包括头痛,注意力、集中力、言语学习和处理速度表现更低。
诊断标准与关键数值
- NeuroPASC组与无COVID对照组细胞因子谱不同(Wald型统计量=44.6,P=.046),NeuroPASC组干扰素-λ1和IFN-λ2/3水平更高。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 原文指出进一步研究将需要建立这些变量之间的机制联系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Neuropsychiatric complications of SARS-CoV-2 infection, also known as neurologic postacute sequelae of SARS-CoV-2 infection (NeuroPASC), affect 10%-60% of infected individuals. There is growing evidence that NeuroPASC is a multi system immune dysregulation disease affecting the brain. The behavioral manifestations of NeuroPASC, such as impaired processing speed, executive function, memory retrieval, and sustained attention, suggest widespread WM involvement. Although previous work has documented WM damage following acute SARS-CoV-2 infection, its involvement in NeuroPASC is less clear. We hypothesized that macrostructural and microstructural WM differences in NeuroPASC participants would accompany cognitive and immune system differences.
MATERIALS AND METHODS: In a cross-sectional study, we screened a total of 159 potential participants and enrolled 72 participants, with 41 asymptomatic controls (NoCOVID) and 31 NeuroPASC participants matched for age, sex, and education. Exclusion criteria included neurologic disorders unrelated to SARS-CoV-2 infection. Assessments included clinical symptom questionnaires, psychometric tests, brain MRI measures, and peripheral cytokine levels. Statistical modeling included separate multivariable regression analyses of GM/WM/CSF volume, WM microstructure, cognitive, and cytokine concentration between-group differences.
RESULTS: NeuroPASC participants had larger cerebral WM volume than NoCOVID controls (β = 0.229; 95% CI: 0.017-0.441; t = 2.16; P = .035). The most pronounced effects were in the prefrontal and anterior temporal WM. NeuroPASC participants also exhibited higher WM mean kurtosis, consistent with ongoing neuroinflammation. NeuroPASC participants had more self-reported symptoms, including headache, and lower performance on measures of attention, concentration, verbal learning, and processing speed. A multivariate profile analysis of the cytokine panel showed different group cytokine profiles (Wald-type-statistic = 44.6, P = .046), with interferon (IFN)-λ1 and IFN-λ2/3 levels higher in the NeuroPASC group.
CONCLUSIONS: NeuroPASC participants reported symptoms of lower concentration, higher fatigue, and impaired cognition compatible with WM syndrome. Psychometric testing confirmed these findings. NeuroPASC participants exhibited larger cerebral WM volume and higher WM mean kurtosis than NoCOVID controls. These findings suggest that immune dysregulation could influence WM properties to produce WM volume increases and consequent cognitive effects and headaches. Further work will be needed to establish mechanistic links among these variables.
引用
- O'Connor EE, Salerno-Goncalves R, Rednam N, et al. Macro- and Microstructural White Matter Differences in Neurologic Postacute Sequelae of SARS-CoV-2 Infection. AJNR Am J Neuroradiol. 2024. PMID: 39389778. doi:10.3174/ajnr.A8481
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。